Shares of Pro Medicus (ASX: PME) plummeted 5.01% in Friday's trading session, extending recent losses for the health imaging technology company. The sharp decline comes despite some analysts remaining bullish on the stock's long-term growth potential.

Pro Medicus, which provides radiology information systems and imaging software, has seen its stock price pull back significantly in recent weeks. Prior to Friday's drop, the shares had already fallen approximately 20% from their recent highs, according to comments from fund manager Jun Bei Liu of Ten Cap.

Despite the recent selling pressure, Liu continues to view Pro Medicus as an attractive investment opportunity. In a recent interview, she emphasized the company's large addressable market and early stage of growth, stating: "The addressable market is enormous, and Pro Medicus is still in the early stages of tapping into it."

Liu believes the long-term investment thesis for Pro Medicus remains intact, even after the sharp pullback in its share price. She highlighted the stock as one of her top picks, particularly when considering its growth prospects over a five-year time horizon.

While the exact catalyst for Friday's 5% plunge was not immediately clear, it appears to be a continuation of profit-taking and valuation concerns that have weighed on the stock in recent weeks. Pro Medicus has long carried a premium valuation due to its strong growth profile, making it potentially vulnerable to broader market volatility.

Investors will likely be watching closely to see if the stock can find support at current levels or if further declines are ahead in the near-term. However, some analysts clearly believe the long-term opportunity remains compelling for those willing to look past the recent turbulence.